Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)

Stewart J. Tepper¹, Jessica Ailani², Janet H. Ford³, Russell M. Nichols³, Lily Q. Li⁴, Phebe Kemmer⁵, Austin L. Hand⁶, Antje Tockhorn-Heidenreich⁷

1. Department of Neurology, Geisel School of Medicine at Dartmouth, 1 Rope Ferry Rd, Hanover, NH 03755, USA.
2. Department of Neurology, Medstar Georgetown University, 3800 Reservoir Rd NW, Washington DC 20007, USA.
3. Health Outcomes and Real-World Evidence – Biomedicines, Eli Lilly and Company, Lilly Corporate Center, 893 Delaware St, Indianapolis, IN 46225, USA.
4. Clinical, Eli Lilly and Company, Lilly Corporate Center, 893 Delaware St, Indianapolis, IN 46225, USA.
5. Department of Statistics-Neuroscience/Urology, Eli Lilly and Company, Lilly Corporate Center, 893 Delaware St, Indianapolis, IN, 46225, USA.
6. Departments of Statistics, IQVIA, 4820 Emperor Blvd, Durham, NC 27703, USA.
7. GPORWE International, Eli Lilly and Company, 8 Arlington Square West, Downshire Way, Bracknell, RG12 1PU, UK.

Running Title: Galcanezumab and HRQoL and Disability after Failure of 2-4 Migraine Preventive Medication Categories

Correspondence To:
Janet H. Ford, MPH, PhD
Eli Lilly and Company,
Indianapolis, IN 46225, USA

Email ID: ford_janet@lilly.com
Phone number: +1-3172761295
ORCID ID: 0000-0001-7966-7737
**Supplementary Tables**

**Supplementary Table S1. MSQ Items**

|   |                                                                                           |
|---|-------------------------------------------------------------------------------------------|
| 1 | Migraine interfered with how dealt with family.                                            |
| 2 | Migraine interfered with leisure activities.                                              |
| 3 | Difficulty performing work or daily activities due to migraine.                           |
| 4 | Kept from getting much done at work or home due to migraine.                               |
| 5 | Migraine limited ability to concentrate at work or for an activity.                        |
| 6 | Migraine made too tired for work or activities.                                           |
| 7 | Migraine limited the days felt energetic.                                                 |
| 8 | Skipped work or activity due to migraine.                                                 |
| 9 | Often needed help in handling routine tasks.                                               |
| 10| Stopped work or activity due to migraine.                                                  |
| 11| Not gone to social activity due to migraine.                                               |
| 12| Felt frustrated due to migraine.                                                           |
| 13| Felt like a burden due to migraine.                                                        |
| 14| Afraid to disappoint others due to migraine.                                               |
Supplementary Table S2. Prior Preventive Migraine Medication History

| Medication          | Population | Total | GMB | EM | GMB | PBO | GMB | PBO | GMB | PBO | GMB | PBO | GMB | PBO | GMB |
|---------------------|------------|-------|-----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|                     | N = 230    | N = 232 | N = 132 | N = 137 | N = 98 | N = 95 |
| Topiramate          | 176 (76.52) | 175 (75.43) | 103 (78.03) | 102 (74.45) | 73 (74.49) | 73 (76.84) |
| Amitriptyline       | 126 (54.78) | 133 (57.32) | 67 (50.76) | 69 (50.37) | 59 (60.20) | 64 (67.37) |
| Propranolol         | 79 (34.34) | 86 (37.07) | 39 (29.54) | 44 (32.12) | 40 (40.82) | 42 (44.21) |
| Valproic Acid       | 78 (33.91) | 83 (35.77) | 45 (34.10) | 54 (39.42) | 33 (33.67) | 29 (30.53) |
| Botulinum toxin A   | 48 (20.86) | 58 (25.00) | 16 (12.12) | 20 (14.60) | 32 (32.65) | 36 (37.89) |
| Metoprolol          | 47 (20.43) | 47 (20.25) | 28 (21.21) | 33 (24.09) | 19 (19.39) | 14 (14.74) |
| Flunarizine         | 30 (13.0) | 42 (18.10) | 15 (11.36) | 23 (16.79) | 15 (15.31) | 19 (20.00) |
| Candesartan         | 30 (13.04) | 23 (9.91) | 18 (13.64) | 12 (8.76) | 12 (12.24) | 9 (9.47) |
| Lomerizine          | 16 (6.95) | 19 (8.18) | 6 (4.55) | 9 (6.57) | 10 (10.20) | 10 (10.52) |
| Cinnarizine         | 8 (3.47) | 16 (6.90) | 6 (4.55) | 10 (7.30) | 2 (2.04) | 4 (4.21) |
| Gabapentin          | 13 (5.70) | 12 (5.17) | 5 (3.79) | 6 (4.38) | 8 (8.16) | 6 (6.32) |
| Oxetorone           | 12 (5.21) | 11 (4.74) | 5 (3.79) | 5 (3.65) | 7 (7.14) | 6 (6.32) |
| Venlafaxine         | 17 (7.40) | 11 (4.74) | 3 (2.27) | 6 (4.38) | 14 (14.29) | 5 (5.26) |
| Verapamil           | 9 (3.91) | 10 (4.31) | 3 (2.27) | 5 (3.65) | 6 (6.12) | 5 (5.26) |
| Zonisamide          | 12 (5.21) | 10 (4.31) | 5 (3.79) | 7 (5.11) | 7 (7.14) | 3 (3.16) |
| Clonazepam          | 3 (1.30) | 9 (3.88) | 1 (0.76) | 6 (4.38) | 2 (1.45) | 3 (3.16) |
| Traditional Medicine | 2 (0.86) | 8 (3.45) | 1 (0.76) | 3 (2.19) | 1 (1.02) | 5 (5.26) |
| Iprazochromine      | 3 (1.30) | 6 (2.58) | 3 (2.27) | 5 (3.65) | 0 (0) | 1 (1.05) |
| Pregabalin          | 5 (2.17) | 6 (2.58) | 2 (1.50) | 3 (2.19) | 3 (3.06) | 3 (3.16) |
| Naproxen            | 4 (1.73) | 5 (2.15) | 3 (2.30) | 1 (0.73) | 1 (1.02) | 4 (4.21) |
| Nortriptylne        | 7 (3.04) | 5 (2.15) | 3 (2.30) | 3 (2.19) | 4 (4.08) | 2 (2.11) |
| Duloxetine          | 3 (1.30) | 4 (1.72) | 0 (0) | 2 (1.46) | 3 (3.06) | 2 (2.11) |
| Almotriptan         | 3 (1.30) | 3 (1.29) | 2 (1.51) | 1 (0.73) | 1 (1.02) | 2 (2.11) |
| Carbamazepine       | 1 (0.43) | 3 (1.29) | 0 (0) | 3 (2.19) | 1 (1.02) | 0 (0) |
| Dihydroergotamine   | 0 (0) | 3 (1.29) | 0 (0) | 1 (0.73) | 0 (0) | 2 (2.11) |
| Nadolol             | 10 (4.34) | 3 (1.29) | 6 (4.55) | 3 (2.19) | 4 (4.08) | 0 (0) |
| Pizotifen           | 5 (2.17) | 3 (1.29) | 2 (1.51) | 3 (2.19) | 3 (3.06) | 0 (0) |
| Riboflavin          | 3 (1.30) | 3 (1.29) | 2 (1.51) | 0 (0) | 1 (1.02) | 3 (3.16) |
| Sumatriptan         | 2 (0.87) | 3 (1.29) | 2 (1.51) | 2 (1.46) | 0 (0) | 1 (1.05) |
| Others              | 6 (2.61) | 2 (0.86) | 2 (1.51) | 2 (1.46) | 4 (4.08) | 0 (0) |

All data are presented as n (%).

n=number of patients with observation; N=number of patients evaluated in each population cohort.
### Supplementary Table S3. Acute Medication History

| Medication                  | Population | Total population | EM  | GMB  | PBO  | GMB  | PBO  | GMB  |
|-----------------------------|------------|------------------|-----|------|------|------|------|------|
|                             | N = 230    | N = 232          | N = 132 | N = 137 | N = 98 | N = 95 |
| Sumatriptan                 | 98 (42.61) | 77 (33.19)       | 63 (47.73) | 52 (37.96) | 35 (35.71) | 25 (26.32) |
| Ibuprofen                   | 88 (38.26) | 76 (32.76)       | 59 (44.70) | 43 (31.39) | 29 (29.59) | 33 (34.74) |
| Paracetamol                 | 59 (25.65) | 45 (19.40)       | 30 (22.73) | 27 (19.71) | 29 (29.59) | 18 (18.95) |
| Naproxen                    | 32 (13.91) | 34 (14.66)       | 16 (12.12) | 21 (15.33) | 16 (16.33) | 13 (13.68) |
| Rizatriptan                 | 27 (11.74) | 30 (12.93)       | 15 (11.36) | 19 (13.87) | 12 (12.24) | 11 (11.58) |
| Eletriptan                  | 34 (14.78) | 37 (15.95)       | 18 (13.64) | 18 (13.14) | 16 (16.33) | 19 (20.00) |
| Indomethacin                | 20 (8.70)  | 21 (9.05)        | 16 (12.12) | 15 (10.95) | 4 (4.08)   | 6 (6.32)   |
| Zolmitriptan                | 19 (8.26)  | 22 (9.48)        | 9 (6.82)   | 13 (9.49)  | 10 (10.20) | 9 (9.47)   |
| Naratriptan                 | 20 (8.70)  | 21 (9.10)        | 8 (6.06)   | 10 (7.30)  | 12 (12.24) | 11 (11.58) |
| Acetylsalicylic acid;       | 22 (9.57)  | 16 (6.90)        | 12 (9.90)  | 8 (5.84)   | 10 (10.20) | 8 (8.42)   |
| Caffeine; Paracetamol       |            |                  |           |           |           |           |
| Metamizole                  | 16 (6.96)  | 12 (5.17)        | 8 (6.06)   | 7 (5.11)   | 8 (8.16)   | 5 (5.26)   |
| Nimuselide                  | 16 (6.96)  | 11 (4.74)        | 13 (9.85)  | 7 (5.11)   | 3 (3.06)   | 4 (4.21)   |
| Acetylsalicylic acid        | 7 (3.04)   | 8 (3.45)         | 5 (3.79)   | 6 (4.38)   | 2 (2.04)   | 2 (2.11)   |
| Dextropropionate            | 10 (4.35)  | 10 (4.31)        | 4 (3.03)   | 6 (4.38)   | 6 (6.12)   | 4 (4.21)   |
| Diclofenac                  | 21 (9.13)  | 8 (3.45)         | 10 (7.58)  | 5 (3.65)   | 11 (11.22) | 3 (3.16)   |
| Almotriptan                 | 11 (4.78)  | 8 (3.45)         | 4 (3.03)   | 4 (2.92)   | 7 (7.14)   | 4 (4.21)   |

All data are presented as n (%).

n=number of patients with observation; N=number of patients evaluated in each population cohort.
### Supplementary Table S4. MSQ RF-R Category Shift in Subpopulations with EM and CM at Month 3 – Double-Blind Period

#### MSQ RF-R Category Shift

|                   | Baseline | Placebo/GMB (N=127) | GMB/GMB (N=135) |
|-------------------|----------|---------------------|-----------------|
|                   | Minimal (None) | Mildly (Mild) | Moderately (Mod) | Severely (Sev) | Extremely (Ext) | Total (Tot) | Minimal (None) | Mildly (Mild) | Moderately (Mod) | Severely (Sev) | Extremely (Ext) | Total (Tot) |
|                   | 0 (0) a  | 2 (1.57) a  | 4 (3.15) b   | 3 (2.36) a  | 0 (0) a  | 1 (0.74) a  | 0 (0) a  | 0 (0) a  | 0 (0) a  | 0 (0) a  | 0 (0) a  | 1 (0.74) a  |
|                   | 1 (0.79) a  | 1 (0.79) a  | 7 (5.51) b   | 5 (3.94) a  | 1 (0.79) a  | 30 (23.62) d | 14 (10.37) c | 8 (5.93) b  | 17 (12.59) c  | 2 (1.48) a  | 0 (0) a  | 3 (2.22) a  |
|                   | 2 (1.57) a  | 0 (0) a  | 13 (10.24) c | 2 (1.57) a  | 52 (40.94) c | 16 (11.85) c | 11 (8.15) b  | 18 (13.33) c  | 14 (10.37) c  | 3 (2.22) a  | 62 (45.93) c  |
|                   | 0 (0) a  | 1 (1.05) b  | 6 (4.72) a  | 15 (11.81) c | 37 (29.13) d | 2 (1.48) a  | 8 (5.93) b  | 6 (4.44) a  | 8 (5.93) b  | 4 (2.96) a  | 28 (20.74) d  |
|                   | 0 (0) a  | 0 (0) a  | 0 (0) a  | 0 (0) a  | 127 (100) e | 36 (26.67) d | 27 (20) a  | 41 (30.37) d  | 24 (17.78) c  | 7 (5.19) b  | 135 (100) e  |

|                   | CM       | Placebo/GMB (N=95) | GMB/GMB (N=88) |
|-------------------|----------|---------------------|-----------------|
|                   | Minimal (None) | Mildly (Mild) | Moderately (Mod) | Severely (Sev) | Extremely (Ext) | Total (Tot) | Minimal (None) | Mildly (Mild) | Moderately (Mod) | Severely (Sev) | Extremely (Ext) | Total (Tot) |
|                   | 0 (0) a  | 0 (0) a  | 2 (2.11) b  | 1 (0.95) a  | 0 (0) a  | 1 (1.05) a  | 0 (0) a  | 0 (0) a  | 0 (0) a  | 0 (0) a  | 0 (0) a  | 1 (1.14) b  |
|                   | 2 (2.11) b  | 0 (0) a  | 8 (8.42) b  | 4 (4.21) a  | 1 (1.05) a  | 17 (17.89) c | 6 (6.82) b  | 4 (4.55) a  | 7 (7.95) b  | 2 (2.27) a  | 0 (0) a  | 19 (21.59) d |
|                   | 3 (3.16) a  | 5 (5.26) b  | 23 (24.21) d | 4 (4.21) a  | 36 (37.89) c | 6 (6.82) b  | 4 (4.55) a  | 18 (20.45) d | 4 (4.55) a  | 2 (2.27) a  | 34 (38.64) c |
|                   | 0 (0) a  | 2 (2.11) b  | 13 (13.68) c | 21 (22.11) d | 38 (40) c  | 1 (1.14) a  | 5 (5.68) b  | 12 (13.64) c | 4 (4.55) a  | 12 (13.64) c | 34 (38.64) c  |
|                   | 0 (0) a  | 17 (17.89) c | 40 (42.11) c | 26 (27.37) d | 95 (100) e  | 13 (14.77) c | 14 (15.91) e | 37 (42.05) e | 10 (11.36) b | 14 (15.91) e | 88 (100) e  |

All data are presented as n (%).
CM=chronic migraine; EM=episodic migraine; GMB=galcanezumab; MIDAS=Migraine Disability Assessment; n=number of patients with observation; N=number of patients evaluated in each population cohort at different time points; PBO=placebo; RF-R=Role Function-Restrictive
Cut-offs: a = 0% to 5%; b = 5% to 10%; c = 10% to 20%; d = 20% to 30%; e ≥30%
### Supplementary Table S5. MIDAS Category Shift in Subpopulations with EM and CM at Month 3 – Double-Blind Period

| MIDAS Category Shift | EM Placebo/GMB (N=127) | GMB/GMB (N=135) |
|----------------------|-------------------------|------------------|
|                      | Baseline                | Placebo/GMB (N=127) | GMB/GMB (N=135) |
|                      | NON (4.72)               | 1 (0.79)          | 1 (0.74)         |
|                      | MIN (1.57)               | 2 (1.57)          | 1 (0.74)         |
|                      | MED (0.79)               | 1 (0.79)          | 1 (0.74)         |
|                      | SEV (1.57)               | 7 (5.51)          | 4 (2.96)         |
|                      | ASV (1.57)               | 0 (0)             | 5 (3.7)          |
|                      | Tot (9.79)               | 9 (6.67)          | 1 (0.74)         |
|                      | NON (0.79)               | 2 (1.57)          | 2 (1.48)         |
|                      | MIN (0.79)               | 1 (0.79)          | 1 (0.74)         |
|                      | MED (0.79)               | 0 (0)             | 0 (0)            |
|                      | SEV (5.51)               | 7 (5.19)          | 7 (5.19)         |
|                      | ASV (1.57)               | 0 (0)             | 6 (4.44)         |
|                      | Tot (9.79)               | 9 (6.67)          | 1 (0.74)         |
|                      | NON (1.57)               | 3 (2.36)          | 5 (1.64)         |
|                      | MIN (2.36)               | 1 (0.79)          | 3 (2.22)         |
|                      | MED (2.36)               | 7 (5.51)          | 3 (2.22)         |
|                      | SEV (2.36)               | 0 (0)             | 2 (1.48)         |
|                      | ASV (2.36)               | 0 (0)             | 0 (0)            |
|                      | Tot (9.79)               | 13 (9.63)         | 12 (8.89)        |
|
### CM Placebo/GMB (N=95) | GMB/GMB (N=135) |
| CM Baseline           | Placebo/GMB (N=95)      | GMB/GMB (N=135) |
|                      | NON (4.21)               | 1 (1.05)          | 1 (1.14)         |
|                      | MIN (0.05)               | 2 (2.11)          | 0 (0)            |
|                      | MED (1.05)               | 0 (0)             | 0 (0)            |
|                      | SEV (1.05)               | 8 (8.42)          | 1 (1.14)         |
|                      | ASV (1.05)               | 0 (0)             | 4 (4.55)         |
|                      | Tot (7.37)               | 7 (7.37)          | 1 (1.14)         |
|                      | NON (0.05)               | 5 (5.26)          | 2 (2.27)         |
|                      | MIN (1.05)               | 0 (0)             | 1 (1.14)         |
|                      | MED (1.05)               | 0 (0)             | 1 (1.14)         |
|                      | SEV (1.05)               | 8 (8.42)          | 1 (1.14)         |
|                      | ASV (1.05)               | 0 (0)             | 2 (2.27)         |
|                      | Tot (7.37)               | 10 (10.53)        | 4 (4.55)         |

All data are presented as n (%).

ASV=Very Severe Limiting Disability; MED=Moderately Limiting Disability; MIN=Mildly Limiting Disability; n=Number of patients with observation; N=Number of patients evaluated in each population cohort at different time points; NON=Little or no disability; SEV=Severely Limiting Disability; TOT=Overall

Cut-offs: a = 0% to 5%; b = 5% to 10%; c = 10% to 20%; d = 20% to 30%; e ≥30%.
| EQ-5D-5L | Total |   |   |   |   |   |
|----------|-------|---|---|---|---|---|
|          | PBO   | GMB |   | PBO| GMB|   |
| Month 3  |       |     |   |    |    |    |
| UK       | N = 225 | N = 227 |   | n = 128 | n = 135 |   |
|          | 0.001 | 0.017 | 0.1630 | -0.010 | 0.011 | 0.2056 |
|          | -0.002 | 0.013 | 0.1267 | -0.009 | 0.008 | 0.1651 |
| US       | LS Mean diff. |   |   |   |   |   |
|          | -0.002 | 0.013 | 0.1267 | -0.009 | 0.008 | 0.1651 |
| Month 6  |       |     |   | PBO|    |    |
| UK       | N = 213 | N = 215 |   | n = 124 | n = 131 |   |
|          | 0.03 | 0.04 | 0.6108 | 0.04 | 0.03 | 0.4357 |
|          | 0.03 | 0.03 | 0.5477 | 0.03 | 0.02 | 0.4889 |
| US       | LS Mean diff. |   |   |   |   |   |
|          | 0.03 | 0.03 | 0.5477 | 0.03 | 0.02 | 0.4889 |

All data are presented as LS mean change from baseline.

*Baseline (last measure before the first dose date) to last post-baseline result.

p-value comparison between LS mean change in GMB group vs. LS mean change in PBO group

CM=chronic migraine; EM=episodic migraine; EF=Emotional Function; GMB=galcanezumab; LS mean=least square mean; N=number of patients evaluated in each population cohort at different time points; PBO=placebo.
### Supplementary Table S7. Response to EQ-5D Domains – Total Population

| Question/Responses | Baseline (N=230) | Month 3 (N=232) | Month 6 (N=225) |
|--------------------|------------------|-----------------|-----------------|
| **Mobility**       |                  |                 |                 |
| No Problem         | 230 (100.00)     | 232 (100.00)    | 213 (100.00)    |
| Slight Problem     | 206 (89.57)      | 203 (87.50)     | 195 (87.84)     |
| Moderate Problem   | 3 (1.30)         | 8 (3.45)        | 8 (3.60)        |
| Severe Problem     | 1 (0.43)         | 0 (0)           | 1 (0.45)        |
| Extreme Problem    | 0 (0)            | 0 (0)           | 0 (0)           |
| **Self-Care**      | 230 (100.00)     | 232 (100.00)    | 222 (100.00)    |
| No Problem         | 227 (98.70)      | 221 (95.26)     | 213 (95.95)     |
| Slight Problem     | 1 (0.43)         | 10 (4.31)       | 9 (4.05)        |
| Moderate Problem   | 2 (0.87)         | 1 (0.43)        | 2 (0.90)        |
| Severe Problem     | 0 (0)            | 0 (0)           | 0 (0)           |
| Extreme Problem    | 0 (0)            | 0 (0)           | 0 (0)           |
| **Usual Activities** | 230 (100.00)    | 232 (100.00)    | 222 (100.00)    |
| No Problem         | 151 (65.65)      | 160 (68.97)     | 158 (71.17)     |
| Slight Problem     | 48 (20.87)       | 46 (19.83)      | 41 (18.47)      |
| Moderate Problem   | 26 (11.30)       | 18 (7.76)       | 16 (7.21)       |
| Severe Problem     | 5 (2.17)         | 7 (3.02)        | 4 (1.80)        |
| Extreme Problem    | 0 (0)            | 1 (0.43)        | 0 (0)           |
| **Pain/Discomfort** | 230 (100.00)   | 232 (100.00)    | 222 (100.00)    |
| No Pain or Discomfort | 74 (32.17)  | 74 (31.90)      | 68 (30.63)      |
| Slight Pain or Discomfort | 92 (40.00) | 82 (35.34)      | 97 (43.69)      |
| Moderate Pain or Discomfort | 47 (20.43) | 52 (22.41)      | 46 (20.72)      |
| Severe Pain or Discomfort | 17 (7.39) | 23 (9.91)       | 10 (4.50)       |
| Extreme Pain or Discomfort | 0 (0)  | 1 (0.43)        | 1 (0.45)        |
| **Anxiety/Depression** | 230 (100.00)  | 232 (100.00)    | 222 (100.00)    |
| No Pain or Discomfort | 74 (32.17)  | 74 (31.90)      | 68 (30.63)      |
| Slight Pain or Discomfort | 92 (40.00) | 82 (35.34)      | 97 (43.69)      |
| Moderate Pain or Discomfort | 47 (20.43) | 52 (22.41)      | 46 (20.72)      |
| Severe Pain or Discomfort | 17 (7.39) | 23 (9.91)       | 10 (4.50)       |
| Extreme Pain or Discomfort | 0 (0)  | 1 (0.43)        | 1 (0.45)        |
|                          | 1st Week | 2nd Week | 3rd Week | 4th Week | 5th Week | 6th Week |
|--------------------------|----------|----------|----------|----------|----------|----------|
| Not Anxious or Depressed | 154 (66.96) | 155 (66.81) | 146 (65.77) | 153 (68.92) | 156 (73.24) | 153 (71.16) |
| Slight Anxious or Depressed | 54 (23.48) | 61 (26.29) | 54 (24.32) | 52 (23.42) | 40 (18.78) | 41 (19.07) |
| Moderately Anxious or Depressed | 19 (8.26) | 9 (3.88) | 15 (6.76) | 14 (6.31) | 14 (6.57) | 18 (8.37) |
| Severely Anxious or Depressed | 2 (0.87) | 6 (2.59) | 6 (2.70) | 1 (0.45) | 3 (1.41) | 1 (0.47) |
| Extremely Anxious or Depressed | 1 (0.43) | 1 (0.43) | 1 (1.35) | 2 (0.90) | 0 (0) | 2 (0.93) |

All data are presented as n (%).

n=number of patients with observation; N=number of patients evaluated in each population cohort at different time points.
| Question/Responses | Baseline (N=132) | GMB120mg (N=137) | Month 3 (N=132) | GMB120mg (N=137) | Month 6 (N=129) | GMB120mg (N=135) |
|-------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| **Mobility**      |                  |                  |                  |                  |                  |                  |
| No Problem        | 132 (100.00)     | 137 (100.00)     | 127 (100.00)     | 134 (100.00)     | 124 (100.00)     | 131 (100.00)     |
| Slight Problem    | 123 (93.18)      | 124 (90.51)      | 113 (88.98)      | 120 (89.55)      | 113 (91.13)      | 116 (88.55)      |
| Moderate Problem  | 7 (5.30)         | 10 (7.30)        | 9 (7.09)         | 9 (6.72)         | 9 (7.26)         | 12 (9.16)        |
| Severe Problem    | 1 (0.76)         | 0 (0)            | 1 (0.79)         | 0 (0)            | 0 (0)            | 0 (0)            |
| Extreme Problem   | 0 (0)            | 0 (0)            | 0 (0)            | 0 (0)            | 0 (0)            | 0 (0)            |
| **Self-Care**     |                  |                  |                  |                  |                  |                  |
| No Problem        | 132 (100.00)     | 137 (100.00)     | 127 (100.00)     | 134 (100.00)     | 124 (100.00)     | 131 (100.00)     |
| Slight Problem    | 131 (99.24)      | 130 (94.89)      | 125 (98.43)      | 129 (96.27)      | 121 (97.58)      | 126 (96.18)      |
| Moderate Problem  | 0 (0)            | 7 (5.11)         | 0 (0)            | 5 (3.73)         | 2 (1.61)         | 5 (3.82)         |
| Severe Problem    | 1 (0.76)         | 0 (0)            | 1 (0.79)         | 0 (0)            | 1 (0.81)         | 0 (0)            |
| Extreme Problem   | 0 (0)            | 0 (0)            | 0 (0)            | 0 (0)            | 0 (0)            | 0 (0)            |
| **Usual Activities** |              |                  |                  |                  |                  |                  |
| No Problem        | 132 (100.00)     | 137 (100.00)     | 127 (100.00)     | 134 (100.00)     | 124 (100.00)     | 131 (100.00)     |
| Slight Problem    | 96 (72.73)       | 103 (75.18)      | 100 (78.74)      | 100 (74.63)      | 110 (88.71)      | 104 (79.39)      |
| Moderate Problem  | 22 (16.67)       | 23 (16.79)       | 21 (16.54)       | 28 (20.90)       | 10 (8.06)        | 23 (17.56)       |
| Severe Problem    | 13 (9.85)        | 7 (5.11)         | 4 (3.15)         | 4 (2.99)         | 4 (3.23)         | 3 (2.29)         |
| Extreme Problem   | 1 (0.76)         | 3 (2.19)         | 2 (1.57)         | 1 (0.75)         | 0 (0)            | 0 (0)            |
| **Pain/Discomfort** |            |                  |                  |                  |                  |                  |
| No Pain or Discomfort | 132 (100.00) | 137 (100.00)  | 127 (100.00)     | 134 (100.00)     | 124 (100.00)     | 131 (100.00)     |
| Slight Pain or Discomfort | 57 (43.18) | 55 (40.15)  | 50 (39.37)       | 64 (47.76)       | 71 (57.26)       | 73 (55.73)       |
| Moderate Pain or Discomfort | 44 (33.33) | 45 (32.85)  | 56 (44.09)       | 49 (36.57)       | 39 (31.45)       | 44 (33.59)       |
| Severe Pain or Discomfort | 23 (17.42) | 23 (16.79)  | 17 (13.39)       | 18 (13.43)       | 14 (11.29)       | 14 (10.69)       |
| Extreme Pain or Discomfort | 8 (6.06)  | 14 (10.22)  | 4 (3.15)         | 3 (2.24)         | 0 (0)            | 0 (0)            |
| Extreme Pain or Discomfort | 0 (0) | 0 (0)  | 0 (0)            | 0 (0)            | 0 (0)            | 0 (0)            |
| Anxiety/Depression                | 132 (100.00) | 137 (100.00) | 127 (100.00) | 134 (100.00) | 124 (100.00) | 131 (100.00) |
|----------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Not Anxious or Depressed        | 95 (71.97)   | 96 (70.07)   | 93 (73.23)   | 92 (68.66)   | 99 (79.84)   | 99 (75.57)   |
| Slight Anxious or Depressed     | 26 (19.70)   | 35 (25.55)   | 26 (20.47)   | 35 (26.12)   | 20 (16.13)   | 23 (17.56)   |
| Moderately Anxious or Depressed | 11 (8.33)    | 4 (2.92)     | 5 (3.94)     | 6 (4.48)     | 4 (3.23)     | 8 (6.11)     |
| Severely Anxious or Depressed   | 0 (0)        | 2 (1.46)     | 3 (2.36)     | 0 (0)        | 1 (0.81)     | 0 (0)        |
| Extremely Anxious or Depressed  | 0 (0)        | 0 (0)        | 0 (0)        | 1 (0.75)     | 0 (0)        | 1 (0.76)     |

All data are presented as n (%).
n=number of patients with observation; N=number of patients evaluated in each population cohort at different time points.
| Question/Responses | Baseline (N=98) | Month 3 (N=95) | Month 6 (N=96) |
|-------------------|-----------------|----------------|----------------|
| Mobility          |                 |                |                |
| No Problem        | 98 (100.00)     | 95 (100.00)    | 89 (100.00)    |
| Slight Problem    | 83 (84.69)      | 79 (83.16)     | 88 (100.00)    |
| Moderate Problem  | 13 (13.27)      | 11 (11.58)     | 9 (9.09)       |
| Severe Problem    | 2 (2.04)        | 5 (5.26)       | 4 (4.55)       |
| Extreme Problem   | 0 (0)           | 0 (0)          | 1 (1.14)       |
| Self-Care         |                 |                |                |
| No Problem        | 98 (100.00)     | 95 (100.00)    | 89 (100.00)    |
| Slight Problem    | 96 (97.96)      | 91 (95.79)     | 84 (95.45)     |
| Moderate Problem  | 1 (1.02)        | 3 (3.16)       | 4 (4.55)       |
| Severe Problem    | 0 (0)           | 0 (0)          | 0 (0)          |
| Extreme Problem   | 0 (0)           | 0 (0)          | 0 (0)          |
| Usual Activities  |                 |                |                |
| No Problem        | 98 (100.00)     | 95 (100.00)    | 89 (100.00)    |
| Slight Problem    | 55 (56.12)      | 57 (60.00)     | 58 (65.91)     |
| Moderate Problem  | 26 (26.53)      | 23 (24.21)     | 20 (21.05)     |
| Severe Problem    | 13 (13.27)      | 11 (11.58)     | 12 (12.63)     |
| Extreme Problem   | 4 (4.08)        | 4 (4.21)       | 2 (2.11)       |
| Pain/Discomfort   |                 |                |                |
| No Pain or Discomfort | 17 (17.35) | 19 (20.00)     | 18 (18.95)     |
| Slight Pain or Discomfort | 48 (48.98) | 37 (38.95)     | 41 (43.16)     |
| Moderate Pain or Discomfort | 24 (24.49) | 29 (30.53)     | 29 (30.53)     |
| Severe Pain or Discomfort | 9 (9.18)      | 9 (9.47)       | 6 (6.32)       |
| Extreme Pain or Discomfort | 0 (0)         | 1 (1.05)       | 1 (1.05)       |
| Anxiety/Depression|                 |                |                |
| No Problem        | 98 (100.00)     | 95 (100.00)    | 89 (100.00)    |
| Slight Problem    | 6 (6.32)        | 6 (6.32)       | 8 (9.09)       |
| Moderate Problem  | 0 (0)           | 1 (1.05)       | 1 (1.14)       |
| Severe Problem    | 0 (0)           | 0 (0)          | 0 (0)          |
| Extreme Problem   | 0 (0)           | 1 (1.19)       | 1 (1.19)       |
| Anxiety Level                  | 1 | 2 | 3 | 4 | 5 | 6 |
|-------------------------------|----|----|----|----|----|----|
| Not Anxious or Depressed      | 59 (60.20) | 59 (62.11) | 53 (55.79) | 61 (69.32) | 57 (64.04) | 54 (64.29) |
| Slight Anxious or Depressed   | 28 (28.57) | 26 (27.37) | 28 (29.47) | 17 (19.32) | 20 (22.47) | 18 (21.43) |
| Moderately Anxious or Depressed | 8 (8.16) | 5 (5.26) | 10 (10.53) | 8 (9.09) | 10 (11.24) | 10 (11.90) |
| Severely Anxious or Depressed | 2 (2.04) | 4 (4.21) | 3 (3.16) | 1 (1.14) | 2 (2.25) | 1 (1.19) |
| Extremely Anxious or Depressed | 1 (1.02) | 1 (1.05) | 1 (1.05) | 1 (1.14) | 0 (0) | 1 (1.19) |

All data are presented as n (%).
n=number of patients with observation; N=number of patients evaluated in each population cohort at different time points.